P275 Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple negative (TN), HER 2-neu positive (HER 2+) or locally advanced breast cancer (LABC)

Autor:	N. Desses, M. Vassilaki, G. Xepapadakis, C. Georgakopoulos, A. Sioulas, V. Parassiris, C. Kosmidis, M. Tsantekidou, A. Klitsa, C. Tsionou
Rok vydání:	2011
Předmět:	Oncology medicine.medical_specialty Cyclophosphamide business.industry medicine.medical_treatment Platinum compounds Locally advanced Weekly paclitaxel General Medicine medicine.disease Regimen Breast cancer Internal medicine Medicine Surgery Doxorubicin business Adjuvant medicine.drug
Zdroj:	The Breast. 20:S66
ISSN:	0960-9776
DOI:	10.1016/s0960-9776(11)70217-x
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e92a2e0d4b8ad3bd54b2d05934e388df https://doi.org/10.1016/s0960-9776(11)70217-x Zobrazit plný text záznamu Full Text from ScienceDirect